Expression of Fas ligand in human hepatoma cell lines: Role of hepatitis-B virus X (HBX) in induction of Fas ligand

International Journal of Cancer

Volumn 82, Issue 4, 1999, Pages 587-591

  Shin, Eui Cheol ^a   Shin, Jeon Soo ^a   Park, Jeon Han ^a   Kim, Hoguen ^b   Kim, Se Jong ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COCULTURE; FRAMESHIFT MUTATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LEUKEMIA; VIRUS CARCINOGENESIS; VIRUS GENOME;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; FAS LIGAND PROTEIN; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 0032837980     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990812)82:4<587::AID-IJC19>3.0.CO;2-9     Document Type: Article

References (30)

1. AMARO, R.G., MONZON, C.G., GARCIA-BUEY, L., MORENO-OTERO, R., ALONSO, J.L., YAGUE, E., PIVEL, J.P., LOPEZ-CABRERA, M., FERNANDEZ-RUIZ, E. and SANCHEZ-MADRID, F., Induction of tumor-necrosis-factor-α production by human hepatocytes in chronic viral hepatitis. J. exp. Med., 179, 841-848 (1994).
2. BENNETT, M.W., O'CONNELL, J., O-SULLIVAN, G.C., BRADY, C., ROCHE, D., COLLINS, J.K. and SHANAHAN, F., The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas-ligand expression by human esophageal carcinoma. J. Immunol., 160, 5669-5675 (1998).
3. CHLICHLIA, K., BUSSLINGER, M., PETER, M.E., WALCZAK, H., KRAMMER, P.M., SCHIRRMACHER, V. and KHAZAIE, K., ICE-proteases mediate HTLV-1 Tax-induced apoptotic T cell death. Oncogene, 14, 2265-2272 (1997).
4. DHEIN, J., WALCZAK, H., BAUMLER, C., DEBATIN, K.M. and KRAMMER, P.H., Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature (Lond.), 373, 438-441 (1995).
5. GRATAS, C., TOHMA, Y., BARNAS, C., TANIERE, P., HAINAUT, P. and OHGAKI, H., Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res., 58, 2057-2062 (1998).
6. GRIFFITH, T.S. and FERGUSON, T.A., The role of FasL-induced apoptosis in immune privilege. Immunol. Today, 18, 240-244 (1997).
7. HAHNE, M., RIMOLDI, D., SCHROTER, M., ROMERO, P., SCHREIER, M., FRENCH, L.E., SCHNEIDER, P., BORNAND, T., FONTANA, A., LIENARD, D., CEROTTINI, J.C. and TSCHOPP, J., Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science, 274, 1363-1366 (1996).
8. HENKLER, F. and KOSHY, R., Hepatitis-B-virus transcriptional activators: mechanisms and possible role in oncogenesis. J. Viral Hepatitis, 3, 109-121 (1996).
9. HUG, H., STRAND, S., GRAMBIHLER, A., GALLE, J., HACK, V., STREMMEL, W., KRAMMER, P.H. and GALLE, P.R., Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J. biol. Chem., 272, 28191-28193 (1997).
10. KAGI, D., VIGNAUX, F., LEDERMANN, B., BURKI, K., DEPRAETERE, V., NAGATA, S., HENGARTNER, H. and GOLSTEIN, P., Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science, 265, 528-530 (1994).
11. KASIBHATLA, S., GENESTIER, L. and GREEN, D.R., Regulation of Fas ligand expression during activation-induced cell death in T lymphocytes via nuclear factor κB. J. biol. Chem., 274, 987-992 (1999).
12. LUO, K.X., ZHU, Y.F., ZHANG, L.X., HE, H.T., WANG X.S. and ZHANG, L., In situ investigation of Fas/FasL expression in chronic hepatitis-B infection and related liver diseases. J. Viral Hepatitis, 4, 303-307 (1997).
13. MATSUI, K., OMURA, S., CUI, H., SCHAUER, S.L., SORENSHEIN, G.E. and JU, S.T., Proteasome regulation of Fas-ligand cytotoxicity. Europ. J. Immunol., 27, 2269-2278 (1997).
14. NAGATA, S., Apoptosis by death factor. Cell, 88, 355-365 (1997).
15. NIEHANS, G.A., BRUNNER, T., FRIZELLE, S.P., LISTON, J.C., SALERNO, C.T., KNAPP, D.J., GREEN, D.R. and KRATZKE, R.A., Human lung carcinomas express Fas ligand. Cancer Res., 57, 1007-1012 (1997).
16. O'CONNELL, J., O'SULLIVAN, G.C., COLLINS, J.K. and SHANAHAN, F., The Fas counterattack: Fas-mediated T-cell killing by colon-cancer cells expressing Fas ligand. J. exp. Med., 184, 1075-1082 (1996).
17. OHTSUKI, T., MICALLEF, M.J., KOHNO, K., TANIMOTO, T., IKEDA, M. and KURIMOTO, M., Interleukin-18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res., 17, 3253-3258 (1997).
18. PARK, J.G., AND 21 OTHERS, Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer, 62, 276-282 (1995).
19. SAAS, P., WALKER, P.R., HAHNE, M., QUIQUEREZ, A.L., SCHNURIGER, V., PERRIN, G., FRENCH, L., VAN MEIR, E.G., TRIBOLET, N., TSCHOPP, J. and DIETRICH, P.Y., Fas-ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. clin. Invest., 99, 1173-1178 (1997).
20. SELLS, M.A., CHEN, M.L. and ACS, G., Production of hepatitis-B-virus particles in Hep G2 cells transfected with cloned hepatitis-B-virus DNA. Proc. nat. Acad. Sci. (Wash.), 84, 1005-1008 (1987).
21. SHIN, E.C., SHIN, J.S., PARK, J.H., KIM, J.J., KIM, H. and KIM, S.J., Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett., 99, 155-162 (1998).
22. SPANDAU, D.F. and LEE, C.H., Trans-activation of viral enhancers by the hepatitis-B-virus X protein. J. Virol., 62, 427-434 (1988).
23. STRAND, S., HOFMANN, W.J., HUG, H., MULLER, M., OTTO, G., STRAND, D., MARIANI, S.M., STREMMEL, W., KRAMMER, P.H. and GALLE, P.R., Lymphocyte apoptosis induced by CD95(Apo-1/Fas)-ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med., 2, 1361-1366 (1996).
24. SUDA, T., TAKAHASHI, T., GOLSTEIN, P. and NAGATA, S., Molecular cloning and expression of the Fas ligand, a novel member of the tumor-necrosis-factor family. Cell, 75, 1169-1178 (1993).
25. TAKAHASHI, T., TANAKA, M., INAZAWA, J., ABE, T., SUDA, T. and NAGATA, S., Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol., 6, 1567-1574 (1994).
26. UNGEFROREN, H., VOSS, M., JANSEN, M., ROEDER, C., HENNE-BRUNS, D., KREMER, B. and KALTHOFF, H., Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res., 58, 1741-1749 (1998).
27. WALKER, P.R., SAAS, P. and DIETRICH, P.Y., Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol., 158, 4521-4524 (1997).
28. WALKER, P.R., SAAS, P. and DIETRICH, P.Y., Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol., 10, 564-572 (1998).
29. WANG, X.W., FORRESTER, K., YEH, H., FEITELSON, M.A., GU, J.R. and HARRIS, C.C., Hepatitis-B-virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. nat. Acad Sci. (Wash.), 91, 2230-2234 (1994).
30. XU, X.N., SCREATON, G.R., GOTCH, F.M., DONG, T., TAN, R., ALMOND, N., WALKER, B., STEBBINGS, R., KENT, K., NAGATA, S., SCOTT, J.E. and MCMICHAEL, A.J., Evasion of cytotoxic T lymphocyte (CTL) responses by Nef-dependent induction of Fas-ligand(CD95L) expression on simianimmunodeficiency-virus-infected cells. J. exp. Med., 186, 7-16 (1997).